Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies

Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies

BioCentury’s Distillery highlights white space cancer targets, new protein degraders and strategies to boost T cell responses to tumors

Durability concerns about lead NK cell therapy overshadow early clinical efficacy data for CAR-NK cell platform

The latest clinical results from Fate adds more fuel to the NK cell momentum kicked off by the company’s 2019 ASH data. Shares of Fate Therapeutics Inc. (NASDAQ:FATE) rose $5.16 to $76.70 on

Acepodia is using its antibody-cell conjugation platform to generate cell therapies for cancer

Indapta streamlines universal allogeneic NK cell development by forgoing genetic engineering